HC Wainwright Reiterates Buy Rating for Moleculin Biotech (NASDAQ:MBRX)
Moleculin Biotech (NASDAQ:MBRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $8.00 price objective on the stock. A number of other analysts have also recently commented on the company. Maxim Group cut Moleculin […]
Moleculin Biotech (NASDAQ:MBRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $8.00 price objective on the stock. A number of other analysts have also recently commented on the company. Maxim Group cut Moleculin […]
